Trials / Completed
CompletedNCT00126997
Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,439 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 11 Months – 21 Months
- Healthy volunteers
- Accepted
Summary
This is a study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals live attenuated measles-mumps-rubella-varicella vaccine given to healthy children in their second year of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Measles, Mumps, Rubella and Chickenpox (live vaccine) |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2005-11-01
- Completion
- 2005-11-01
- First posted
- 2005-08-05
- Last updated
- 2016-09-21
Locations
54 sites across 4 countries: Finland, Germany, Greece, Poland
Source: ClinicalTrials.gov record NCT00126997. Inclusion in this directory is not an endorsement.